(P040) Gastrointestinal Impact of Proton Radiation to the Spine in Pediatric Patients

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Radiation to the spine may be associated with gastrointestinal (GI) toxicity, including nausea, vomiting, anorexia, and esophagitis. Proton therapy is expected to reduce this due to decreased exposure of the GI system when posterior-anterior beams are utilized.

Table P040

Christine E. Hill-Kayser, MD, Stefan Both, PhD, Zelig Tochner, MD, Robert A. Lustig, MD; Perelman School of Medicine, University of Pennsylvania

Introduction: Radiation to the spine may be associated with gastrointestinal (GI) toxicity, including nausea, vomiting, anorexia, and esophagitis. Proton therapy is expected to reduce this due to decreased exposure of the GI system when posterior-anterior beams are utilized.

Methods: A consecutive series of 31 pediatric patients received proton therapy to the spine using posterior beams at the Children’s Hospital of Philadelphia/Roberts Proton Therapy Institute. Gastrointestinal dosimetry was evaluated at the time of radiation planning. Acute toxicities were evaluated weekly during proton therapy.

Results: A total of 32 patients (15 male) were evaluated; average age was 12 years (range: 2–20 yr). Of them, 25 received radiation to the total spine, and 6 received radiation to the partial spine (4 thoracic, 2 lumbar, 1 cervical). For those requiring total spine radiation, matchline changes were performed after each 900 cGy relative biological effectiveness (RBE). Proton radiotherapy dose ranged from 2,340 cGy (RBE) to 7,200 cGy (RBE), depending on clinical factors, and 19 patients received concurrent chemotherapy. Proton dosimetry to the esophagus, stomach, and bowel was evaluated at the time of radiation planning. Dose to the stomach and bowel was essentially 0 for all patients. Esophageal dose was very heterogeneous, with maximum ranging from near 0 to 6,180 cGy (RBE), and mean dose was < 1,000 cGy for all patients. Anorexia was the most common acute GI toxicity, affecting 16 patients (50%), followed by nausea (15, 47%) and constipation (10, 31%) (Table). The majority of GI effects were grade (G) 1 or 2, although four patients experienced G3 anorexia, one experienced G3 esophagitis, and one experienced G3 nausea. Dosimetry for the patient with G3 esophagitis demonstrated a maximum radiation dose of 2,120 cGy; however, the patient required daily intubation for anesthesia and also received chemotherapy concurrently. No patient experienced G4 acute GI toxicity.

Conclusions: Pediatric patients who were treated with proton therapy to the spine using posterior fields developed relatively mild acute toxicity, with > grade 2 acute toxicity rare. Some patients did experience bothersome anorexia and nausea. These side effects will continue to require support from the clinical team, despite improved dosimetry to the GI tract with use of proton radiotherapy.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Related Content